Contribute Try STAT+ Today

Drugs that harness the body’s immune system to find and kill cancer cells have improved the lives of patients with cancer and generated billions of dollars in sales for the companies that develop them. But a majority of cancer patients still don’t benefit from immunotherapies, so the work to discover and develop even more effective therapies continues.

Adam Feuerstein, STAT’s senior writer and national biotech columnist, examines some of the most promising areas of cancer immunotherapy research. He’ll explain how a better understanding of tumor biology is helping researchers exploit new immune-based targets, and he’ll explore the different technologies — from CAR-Ts and antibodies to viruses and mRNA — that are being deployed against them.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.